Sol-Gel Technologies Ltd. Ordinary Shares (SLGL) Stock Price

SLGLStock

$64.25+58.60%52W

Market Cap$210.35M

P/E—

PEG Ratio—

Div yield—

Beta1.26

SLGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-25.92%

Price vs S&P 500 (4W)9.71%

VGM Score34.01

P/CF (Annual)653.27x

Book Value / Share (Quarterly)$14.69

P/TBV (Annual)0.92x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)70.96%

Cash Flow / Share (Quarterly)$-2.62

Price vs S&P 500 (YTD)40.54%

Net Profit Margin (TTM)-910.14%

EPS (TTM)$-5.64

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-5.64

Revenue Growth (5Y)17.19%

EPS (Annual)$-2.20

ROI (Annual)-26.86%

Net Profit Margin (5Y Avg)-450.06%

Cash / Share (Quarterly)$14.64

Revenue Growth QoQ (YoY)-96.58%

ROA (Last FY)-20.48%

Revenue Growth TTM (YoY)-92.50%

EBITD / Share (TTM)$-2.47

ROE (5Y Avg)-32.71%

Operating Margin (TTM)-986.96%

Cash Flow / Share (Annual)$0.10

P/B Ratio4.37x

P/B Ratio (Quarterly)5.04x

Net Income / Employee (Annual)$-218,800

EV / Revenue (TTM)107.91x

Net Interest Coverage (TTM)-1037.50x

ROA (TTM)-36.96%

EV / EBITDA (TTM)24.43x

EPS Incl Extra (Annual)$-2.20

Current Ratio (Annual)4.37x

Quick Ratio (Quarterly)9.87x

3-Month Avg Trading Volume0.05M

52-Week Price Return58.60%

EV / Free Cash Flow (Annual)704.34x

Revenue / Employee (TTM)$64,100

Tangible BV / Share (Quarterly)$1.74

P/S Ratio (Annual)10.85x

Asset Turnover (Annual)0.65x

52-Week High$97.97

Operating Margin (5Y Avg)-487.58%

EPS Excl Extra (Annual)$-2.20

CapEx CAGR (5Y)-36.35%

26-Week Price Return-16.01%

Quick Ratio (Annual)4.21x

13-Week Price Return-22.78%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.37x

Enterprise Value$193.69M

Revenue / Share Growth (5Y)78.08%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)26.85%

Revenue / Employee (Annual)$692,400

Pretax Margin (Annual)-31.60%

Cash / Share (Annual)$8.61

3-Month Return Std Dev74.63%

Net Income / Employee (TTM)$-583,500

ROE (Last FY)-26.86%

EPS Basic Excl Extra (Annual)$-2.20

Receivables Turnover (TTM)0.33x

EV / Free Cash Flow (TTM)941.22x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.64

Receivables Turnover (Annual)6.97x

ROI (TTM)-44.05%

P/S Ratio (TTM)117.19x

Pretax Margin (5Y Avg)-450.06%

Revenue / Share (Annual)$6.96

Tangible BV / Share (Annual)$1.83

Price vs S&P 500 (52W)43.07%

Year-to-Date Return52.47%

5-Day Price Return-11.26%

EPS Normalized (Annual)$-2.20

ROA (5Y Avg)-27.50%

Net Profit Margin (Annual)-31.60%

Month-to-Date Return-13.50%

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-38.88%

P/CF (TTM)835.32x

ROI (5Y Avg)-32.71%

EPS Basic Excl Extra (TTM)$-5.64

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)5.15x

Pretax Margin (TTM)-910.14%

Book Value / Share (Annual)$8.19

Price vs S&P 500 (13W)-25.46%

Beta1.26x

P/FCF (Annual)764.93x

Revenue / Share (TTM)$0.55

ROE (TTM)-44.05%

52-Week Low$28.81

vGradeF

gGradeD

mGradeC

vgmGradeD

SLGL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 20, 2026	-$2.31	-$1.13	+51.08%(+$1.18)
Q1 2026	May 28, 2026	-$2.86	-$1.31	+54.20%(+$1.55)
Q4 2025	Mar 19, 2026	$0.39	-$1.06	-371.79%(-$1.45)
Q3 2025	Nov 20, 2025	-$2.09	-$2.13	-1.91%(-$0.04)
Q2 2025	Aug 15, 2025	—	$4.17	—

SLGL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

4.10

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SLGLSol-Gel Technologies Ltd. Ordinary Shares	F	D	C	117.2x	-92.5%	—	—	$64.25
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Sol-Gel Technologies Ltd. Ordinary Shares

Sol-Gel Technologies develops branded and generic topical pharmaceuticals for dermatology, with a focus on rare skin diseases. Its lead asset, SGT-610 (Patidegib Gel 2%), is a hedgehog pathway blocker targeting basal cell carcinoma prevention in Gorlin syndrome. The company also develops SGT-210 for rare keratosis-related indications such as Darier Disease, PC, PPK, and Olmsted.

SLGL Next Earnings Report

Report dateNov 19, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$2.07

Revenue estimate$150,000

Also reporting on Nov 19, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

SLGL Insider Transactions

BuySep 11, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 3,124Value: $207,399
BuySep 9, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 9,976Value: $687,160
BuySep 2, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 1,683Value: $116,488
BuyAug 31, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 40,330Value: $2.79M
BuyAug 12, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 951Value: $67,996

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

SABSSAB Biotherapeutics, Inc. Common StockBiological Products
LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$28.81

High$97.97